Biomed-Lublin Wytwórnia Surowic i Szczepionek has made a decision to change the current financing structure of its projects, ie to convert loans into capital, the company said. Biomed has concluded an investment and offering agreement with Ipopema Securities, under which Ipopema will acquire up to 3 million shares of the company.
Implementation of the next stage of the above-mentioned projects is related to the updating of their financing assumptions.
Biomed today announced that it has signed an investment and offer agreement with Ipopema Securities for the issue of up to 3,000,000 shares of the company as part of the target capital.
The agreement obliges Ipopema Securities to issue up to 3,000,000 ordinary bearer shares as part of the company’s authorized capital and obliges Ipopema to acquire a new share issue. As stated, in order to fulfill its obligation, Ipopema intends to borrow directly or by designating an entity that will borrow 3,000,000 shares of the company from selected shareholders.
The shares taken up by Ipopema will be returned to the existing shareholders of the company who borrowed the shares after obtaining the status of shares admitted to trading on the stock exchange.
Biomed-Lublin Wytwórnia Surowic i Szczepionek is a Polish pharmaceutical company operating since 1944. The company produces medicinal preparations (prescription drugs, medical devices and laboratory reagents used in biochemical and medical laboratories). The company has been listed on the main market of the WSE since 2015.